Genotypic resistance to sulfamide drugs among patients with Pneumocystis jiroveci pneumonia;Resistencia genotipica a sulfamidas en pacientes con neumonía por Pneumocystis jiroveci

Medicina Clinica

Volumn 122, Issue 16, 2004, Pages 617-619

  Calderón, Enrique ^a,b   De La Horrab, Carmen ^a   Montes Cano, Marco Antonio ^a   Respaldiza, Nieves ^a   Martín Juan, José ^a   Varela, José Manuel ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b NONE   (Spain)

Author keywords

Dihydropteroate synthase; Drug resistance; Pneumocystis infection

Indexed keywords

DIHYDROPTEROATE SYNTHASE; SULFANILAMIDE; SULFONAMIDE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HUMAN; LUNG LAVAGE; MALE; MOLECULAR GENETICS; PNEUMOCYSTIS; PNEUMOCYSTIS JIROVECI; PNEUMONIA; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SPAIN; TREATMENT OUTCOME; DRUG EFFECT; ENZYMOLOGY; GENETICS; MICROBIOLOGY; MIDDLE AGED; MUTATION; PNEUMOCYSTIS PNEUMONIA;

ADULT; DIHYDROPTEROATE SYNTHASE; DRUG RESISTANCE, BACTERIAL; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; PNEUMOCYSTIS JIROVECI; PNEUMONIA, PNEUMOCYSTIS; SULFONAMIDES;

EID: 2542583239     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13061066     Document Type: Article

References (10)

1. Stringer JR, Beard CB, Miller RF, Wakefield AE. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis 2002; 8:891-6.
2. Calderón-Sandubete EJ, Varela-Aguilar JM, Medrano-Ortega FJ, Nieto-Guerrero V, Respaldiza-Salas N, De la Horra-Padilla C, et al. Historial perspective on Pneumocystis carinii infection. Protist 2002;153:303-10.
3. Hughes WT, Killmar JT, Oz HS. Relative potency of 10 drugs with anti-Pneumocystis carinii activity in an animal model. J. Infect Dis 1994;170: 906-11.
4. Swedberg G, Ringertz S, Skold O. Sulfonamide resistance in Streptococcus pyogenes is associated with differences in the amino acid sequence of its chromosomal dihydropteroate synthase. Antimicrob Agents Chemother 1998;42:1062-7.
5. Triglia T, Menting JG, Wilson C, Cowman AF. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci USA 1997;94:13944-9.
6. Kazanjian P, Locke AB, Hossler PA, Lane BR, Bartlett MS, Smith JW, et al. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. AIDS 1998; 12:873-8.
7. Helweg-Larsen J, Benfield TL, Eugen-Olsen J, Lundgren JD, Lundgren B. Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. Lancet 1999;354:1347-51.
8. Helweg-Larsen J, Eugen-Olsen J, Lundgren B. Rapid detection of dihydropteroate polymorphism in AIDS-related Pneumocystis carinii pneumonia by restriction fragment length polymorphism. Scand J Infect Dis 2000;32:481-3.
9. Zingale A, Carrera P, Lazzarin A, Scarpellini P. Detection of Pneumocystis carinii and characterization of mutations associated with sulfa resistance in bronchoalveolar lavage samples from human immunodeficiency virus-infected subjects. J Clin Microbiol 2003;41:2709-12.
10. Navin TR, Beard CB, Huang L, Del Río C, Lee S, Pieniazek NJ, et al. Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P. carinii pneumonia in patients with HIV-1: a prospective study. Lancet 2001; 358:545-9.